ClinicalTrials.gg
CompletedNCT05217732Updated Jul 21, 2023

Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

A Phase 1 interventional study of ZX-7101A and Placebo in Safety Issues, Tolerance and Pharmacokinetics, sponsored by Nanjing Zenshine Pharmaceuticals. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-21.

Sponsored by Nanjing Zenshine Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Randomized, double-blind and placebo-controled study to assess the safety, tolerability and pharmacokinetics of single ascending doses of ZX-7101A and its food effect in China healthy adult volunteers. The study is composed of 2 parts. Part 1 is to assess the safety, tolerability and pharmacokinetics of a single ascending doses of ZX-7101A tablet. Part 2 is to assess the food effect on ZX-7101A at a selected dose in a cross-over design.

02

Conditions studied

  • Safety Issues
  • Tolerance
  • Pharmacokinetics
  • Food Effect
03

In context

Lead sponsor

Nanjing Zenshine Pharmaceuticals is the lead sponsor of 16 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults age of 18-45 years old
  • in the range of 9\~26 kg/m2; Bodyweight (male) ≥50kg, Bodyweight (Female) ≥45kg
  • In the judgement of the investigator, no abnormalities identified by a detailed medical history and full physical examination including BP and pulse rate measurement, or clinical laboratory tests
  • Female subjects of nonchildbearing potential must be not pregnant or lactating. Subjects must consent and comply with the requirement of the study.
  • Able to understand the risks involved in the study, and provide written before the first study-specific procedure
  • Able to understand and comply with the study procedures

Exclusion criteria

Exclusion Criteria:

  • History of or allergy to drug or food
  • History of abnormalities such as metabolic, liver, kidney, blood, lung, cardiovascular, gastrointestinal, urinary, endocrine, neurological, or psychiatric disorders; or in the judgement of the investigator, any medical abnormality that may be a concern to participate the study.
  • Tympanic temperature >37.5℃, Pulse >100bmp or \<50bmp, Systolic blood pressure ≥140mHg or ≤90mHg, or Diastolic blood pressure ≥90mHg or\<50mHg
  • Clinically relevant out-of-range baseline of total white cells or
  • Total >1.5x , >1.5 ULN or ALT >1.5ULN
  • Estimated (eGFR) \<90 mL/min/1.73 m2
  • > 450ms ( Fridericia's correction , QTcF=QT/(RR\^0.33) ), QRS>120ms
  • Acute respiratory tract infection within 2 weeks
  • Any condition possibly affecting drug absorption, e.g. gastrectomy
  • Received treatment of any prescription drug or alternative medicine within 4 weeks before first dosing or any nonprescription drug within 2 weeks or 5x half-life, whichever is longer
  • Regular alcohol consumption >14units/week I the past 6 months or positive in alcohol breath test
  • Use of tobacco or nicotine containing products more than the equivalent of 5 cigarettes per day within 3 months
  • Unwilling or unable to restrict the intake of caffeine or alcohol within 72 hours before dosing or during the in-patient observation period
  • Use or intake of any known liver enzyme inducer or inhibitor within 14 days
  • History of drug abuse or positive urine drug test
  • Positive test for antibody (HCV), surface antigen (HbsAg), (HIV) antibody, or Syphilis antibody at Screening
  • Accumulative blood donation >400ml within 3 months or >200ml within 4 weeks or planning to donate during the study
  • Pregnancy or lactating at screening
  • Having difficulty of drawing blood from vein
  • Treatment with an drug or procedure within 3 months
  • Received vaccination within 3 months or plan to be received vaccine during the study
  • Received any surgical procedure within 3 months at screening
  • Any other reason that, in the opinion of the investigator, unlikely to comply with the clinical study protocol or is unsuitable for any other reason.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Single dose of ZX-7101A treatment A

    Administrated as a single oral dose in healthy subjects

    Drug: ZX-7101A · Drug: Placebo

  • Experimental
    Single dose of ZX-7101A treatment B

    Administrated as a single oral dose in healthy subjects

    Drug: ZX-7101A · Drug: Placebo

  • Experimental
    Single dose of ZX-7101A treatment C

    Administrated as a single oral dose in healthy subjects

    Drug: ZX-7101A · Drug: Placebo

  • Experimental
    Single dose of ZX-7101A treatment D

    Administrated as a single oral dose in healthy subjects

    Drug: ZX-7101A · Drug: Placebo

  • Experimental
    Single dose of ZX-7101A treatment E

    Administrated as a single oral dose in healthy subjects

    Drug: ZX-7101A · Drug: Placebo

  • Experimental
    ZX-7101A food effect

    Administered as a selected, single oral dose of ZX-7101A in fasting state and non-fasting (with food) state.

    Drug: ZX-7101A

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse effect (TEAEs) and severe adverse events (SAEs)

    safety and tolerability

    Time frame: Day 1-day15

Secondary outcomes

  1. Peak plama concentration of ZX-7101A

    To evaluate the maximum observed concentration (Cmax) after single oral dose of ZX-7101A

    Time frame: Days 1-15

  2. Area under the plasma concentration of ZX-7101A

    To evaluate the area under the curve (AUC) plasma-concentration after single oral dose of ZX-7101A

    Time frame: Days 1-15

  3. Half-life of ZX-7101A

    To evaluate the half-life of ZX-7101A after single oral dose of ZX-7101A

    Time frame: Days 1-15

  4. Concentration of ZX-7101A in urine

    To evaluate the concentration at a select treatment after single oral dose of ZX-7101A

    Time frame: Days 1-15

07

Study locations

1 site
  • Fudan University affiliated Huashan Hospital
    Shanghai, Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Aug 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2022
First posted
Feb 1, 2022
StartActual
Dec 1, 2021
Primary completionActual
Aug 29, 2022
CompletionActual
Dec 19, 2022
Last update
Jul 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05217732
Lead sponsor
Nanjing Zenshine Pharmaceuticals
Responsible party
Sponsor
First posted
Feb 1, 2022
Start date
Dec 1, 2021
Primary completion
Aug 29, 2022
Completion
Dec 19, 2022
Last update
Jul 21, 2023

Study contacts

Xiaoli Qin, PhD
study director · Zenshine Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sebaloxavir marboxil

Start the discussion